CA3155669A1 - Neisseria meningitidis compositions and methods thereof - Google Patents
Neisseria meningitidis compositions and methods thereofInfo
- Publication number
- CA3155669A1 CA3155669A1 CA3155669A CA3155669A CA3155669A1 CA 3155669 A1 CA3155669 A1 CA 3155669A1 CA 3155669 A CA3155669 A CA 3155669A CA 3155669 A CA3155669 A CA 3155669A CA 3155669 A1 CA3155669 A1 CA 3155669A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- meningitidis
- dose
- serogroup
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 686
- 241000588650 Neisseria meningitidis Species 0.000 title claims abstract description 299
- 238000000034 method Methods 0.000 title claims abstract description 209
- 230000028993 immune response Effects 0.000 claims abstract description 232
- 150000004676 glycans Chemical class 0.000 claims abstract description 142
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 142
- 239000005017 polysaccharide Substances 0.000 claims abstract description 142
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 claims abstract description 140
- 150000001720 carbohydrates Chemical class 0.000 claims description 255
- 229960005486 vaccine Drugs 0.000 claims description 243
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 226
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 226
- 229920001184 polypeptide Polymers 0.000 claims description 225
- 230000000844 anti-bacterial effect Effects 0.000 claims description 164
- 229960000814 tetanus toxoid Drugs 0.000 claims description 158
- 229910052799 carbon Inorganic materials 0.000 claims description 147
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 92
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 91
- 229940068968 polysorbate 80 Drugs 0.000 claims description 91
- 229920000053 polysorbate 80 Polymers 0.000 claims description 91
- 210000002966 serum Anatomy 0.000 claims description 89
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 88
- 229910052782 aluminium Inorganic materials 0.000 claims description 70
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 70
- -1 1-cyano-4-dimethylamino pyridinium tetrafluoroborate Chemical compound 0.000 claims description 59
- 229940035144 trumenba Drugs 0.000 claims description 54
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 50
- 239000011780 sodium chloride Substances 0.000 claims description 50
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 49
- 229960002885 histidine Drugs 0.000 claims description 42
- 241000921898 Neisseria meningitidis serogroup A Species 0.000 claims description 39
- 241000947238 Neisseria meningitidis serogroup C Species 0.000 claims description 37
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 37
- 241001573069 Neisseria meningitidis serogroup Y Species 0.000 claims description 36
- 150000001718 carbodiimides Chemical class 0.000 claims description 36
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 34
- 229940124951 Menveo Drugs 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 27
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 21
- 229930006000 Sucrose Natural products 0.000 claims description 21
- 239000005720 sucrose Substances 0.000 claims description 21
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 claims description 18
- 230000001939 inductive effect Effects 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 17
- 150000001413 amino acids Chemical group 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 6
- 101710186862 Factor H binding protein Proteins 0.000 abstract description 202
- 125000003275 alpha amino acid group Chemical group 0.000 description 162
- 108090000623 proteins and genes Proteins 0.000 description 133
- 235000018102 proteins Nutrition 0.000 description 132
- 102000004169 proteins and genes Human genes 0.000 description 132
- 238000002255 vaccination Methods 0.000 description 103
- 102000014914 Carrier Proteins Human genes 0.000 description 89
- 108010078791 Carrier Proteins Proteins 0.000 description 89
- 238000012360 testing method Methods 0.000 description 72
- 239000000725 suspension Substances 0.000 description 70
- 230000002163 immunogen Effects 0.000 description 54
- 230000004044 response Effects 0.000 description 52
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 44
- 108091007433 antigens Proteins 0.000 description 43
- 102000036639 antigens Human genes 0.000 description 43
- 238000003556 assay Methods 0.000 description 43
- 229940126534 drug product Drugs 0.000 description 42
- 239000000825 pharmaceutical preparation Substances 0.000 description 42
- 239000000427 antigen Substances 0.000 description 41
- 208000037909 invasive meningococcal disease Diseases 0.000 description 38
- 239000002245 particle Substances 0.000 description 33
- 201000010099 disease Diseases 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 230000000295 complement effect Effects 0.000 description 31
- 230000005875 antibody response Effects 0.000 description 24
- 125000003277 amino group Chemical group 0.000 description 22
- 230000003053 immunization Effects 0.000 description 22
- 238000002649 immunization Methods 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 19
- 229940031937 polysaccharide vaccine Drugs 0.000 description 19
- 239000006185 dispersion Substances 0.000 description 18
- 230000005847 immunogenicity Effects 0.000 description 18
- 125000003636 chemical group Chemical group 0.000 description 17
- 230000021615 conjugation Effects 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 17
- 210000002418 meninge Anatomy 0.000 description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 14
- 230000027455 binding Effects 0.000 description 14
- 229960003983 diphtheria toxoid Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 13
- 108010060123 Conjugate Vaccines Proteins 0.000 description 13
- 108700026633 Neisseria meningitidis factor H-binding Proteins 0.000 description 13
- 208000037941 meningococcal disease Diseases 0.000 description 13
- 230000001681 protective effect Effects 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 241001212279 Neisseriales Species 0.000 description 12
- 125000000539 amino acid group Chemical group 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 238000000569 multi-angle light scattering Methods 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 9
- 229940031670 conjugate vaccine Drugs 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 229940124731 meningococcal vaccine Drugs 0.000 description 8
- 229940071643 prefilled syringe Drugs 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000006722 reduction reaction Methods 0.000 description 8
- 102000016550 Complement Factor H Human genes 0.000 description 7
- 108010053085 Complement Factor H Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 239000004643 cyanate ester Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 210000004201 immune sera Anatomy 0.000 description 7
- 229940042743 immune sera Drugs 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000035939 shock Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 6
- 101710188053 Protein D Proteins 0.000 description 6
- 101710132893 Resolvase Proteins 0.000 description 6
- 238000006640 acetylation reaction Methods 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 125000002843 carboxylic acid group Chemical group 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 229940088679 drug related substance Drugs 0.000 description 5
- 230000005484 gravity Effects 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 150000002482 oligosaccharides Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000013049 sediment Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 238000011752 CBA/J (JAX™ mouse strain) Methods 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 201000009906 Meningitis Diseases 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000005180 public health Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229940124872 Hepatitis B virus vaccine Drugs 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 241001174901 Neisseria meningitidis alpha275 Species 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 229940124858 Streptococcus pneumoniae vaccine Drugs 0.000 description 3
- XUGUHTGSMPZQIW-UHFFFAOYSA-N [[4-(4-diazonioiminocyclohexa-2,5-dien-1-ylidene)cyclohexa-2,5-dien-1-ylidene]hydrazinylidene]azanide Chemical group C1=CC(N=[N+]=[N-])=CC=C1C1=CC=C(N=[N+]=[N-])C=C1 XUGUHTGSMPZQIW-UHFFFAOYSA-N 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940001442 combination vaccine Drugs 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 229960005097 diphtheria vaccines Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 229960004443 hemophilus influenzae b vaccines Drugs 0.000 description 3
- 229940029583 inactivated polio vaccine Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000006194 liquid suspension Substances 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229960005037 meningococcal vaccines Drugs 0.000 description 3
- 229940031346 monovalent vaccine Drugs 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 229940066827 pertussis vaccine Drugs 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229960002766 tetanus vaccines Drugs 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108010034055 CRM45 fragment of diphtheria toxin Proteins 0.000 description 2
- 208000034628 Celiac artery compression syndrome Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000256257 Heliothis Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010042653 IgA receptor Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000003231 Lowry assay Methods 0.000 description 2
- 238000009013 Lowry's assay Methods 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 108700007374 Neisseria meningitidis NHBA Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 108010013381 Porins Proteins 0.000 description 2
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229940041323 measles vaccine Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 229940095293 mumps vaccine Drugs 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000007739 porin activity proteins Human genes 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 229940023143 protein vaccine Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229960003131 rubella vaccine Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008362 succinate buffer Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 229940021648 varicella vaccine Drugs 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- AWAFMFHOLVZLFG-UHFFFAOYSA-N 1-iodoaziridine-2,3-dione Chemical compound IN1C(=O)C1=O AWAFMFHOLVZLFG-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- ALEBYBVYXQTORU-UHFFFAOYSA-N 6-hydrazinyl-6-oxohexanoic acid Chemical compound NNC(=O)CCCCC(O)=O ALEBYBVYXQTORU-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 108010053406 CRM 107 Proteins 0.000 description 1
- 101100468275 Caenorhabditis elegans rep-1 gene Proteins 0.000 description 1
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229940032024 DPT vaccine Drugs 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 229940124897 Gardasil Drugs 0.000 description 1
- 101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229940124914 Havrix Drugs 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710084218 Master replication protein Proteins 0.000 description 1
- 229940124904 Menactra Drugs 0.000 description 1
- 206010027249 Meningitis meningococcal Diseases 0.000 description 1
- 201000010924 Meningococcal meningitis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 101900047473 Neisseria meningitidis serogroup B Factor H binding protein Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 101710112078 Para-Rep C2 Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 101710183389 Pneumolysin Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- DHZPCJWLUQMUPF-RTRLPJTCSA-N [(2R,3S,4R,5R)-5-acetamido-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl] dihydrogen phosphate Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](OP(O)(O)=O)[C@@H]1O DHZPCJWLUQMUPF-RTRLPJTCSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940102614 adacel Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940090821 bexsero Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229920005557 bromobutyl Polymers 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001606 epiglottitis Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229910001679 gibbsite Inorganic materials 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 238000013038 hand mixing Methods 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 229940035102 meningococcal group b vaccine Drugs 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 238000007392 microtiter assay Methods 0.000 description 1
- 238000012821 model calculation Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- RYRIMPODRHVEIW-UHFFFAOYSA-N n-(2-phenylethyl)nitramide Chemical compound [O-][N+](=O)NCCC1=CC=CC=C1 RYRIMPODRHVEIW-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013193 stability-indicating method Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962907097P | 2019-09-27 | 2019-09-27 | |
| US62/907,097 | 2019-09-27 | ||
| US202063040498P | 2020-06-17 | 2020-06-17 | |
| US63/040,498 | 2020-06-17 | ||
| PCT/IB2020/058928 WO2021059181A1 (en) | 2019-09-27 | 2020-09-24 | Neisseria meningitidis compositions and methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3155669A1 true CA3155669A1 (en) | 2021-04-01 |
Family
ID=72744819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3155669A Pending CA3155669A1 (en) | 2019-09-27 | 2020-09-24 | Neisseria meningitidis compositions and methods thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12383611B2 (enExample) |
| EP (1) | EP4034157A1 (enExample) |
| JP (1) | JP2021066727A (enExample) |
| KR (1) | KR102871663B1 (enExample) |
| CN (1) | CN115605222A (enExample) |
| AU (1) | AU2020355401B2 (enExample) |
| BR (1) | BR112022004921A2 (enExample) |
| CA (1) | CA3155669A1 (enExample) |
| IL (1) | IL291239A (enExample) |
| MX (1) | MX2022003682A (enExample) |
| WO (1) | WO2021059181A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202111092UA (en) * | 2017-01-31 | 2021-11-29 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| GB202208089D0 (en) * | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (273)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| EP0027888B1 (en) | 1979-09-21 | 1986-04-16 | Hitachi, Ltd. | Semiconductor switch |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| CH660375A5 (it) | 1983-02-08 | 1987-04-15 | Sclavo Spa | Procedimento per la produzione di proteine correlate alla tossina difterica. |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
| US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8424757D0 (en) | 1984-10-01 | 1984-11-07 | Pasteur Institut | Retroviral vector |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| EP0232262A4 (en) | 1985-08-15 | 1989-09-19 | Stauffer Chemical Co | TRYPTOPHANE GENERATING MICROORGANISM. |
| US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US5514581A (en) | 1986-11-04 | 1996-05-07 | Protein Polymer Technologies, Inc. | Functional recombinantly prepared synthetic protein polymer |
| US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| RU2023448C1 (ru) | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
| AU3069189A (en) | 1988-02-05 | 1989-08-25 | Trustees Of Columbia University In The City Of New York, The | Retroviral packaging cell lines and processes of using same |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP0432216A1 (en) | 1988-09-01 | 1991-06-19 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| US7118757B1 (en) | 1988-12-19 | 2006-10-10 | Wyeth Holdings Corporation | Meningococcal class 1 outer-membrane protein vaccine |
| US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
| EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| EP0462210B1 (en) | 1989-03-09 | 1994-09-07 | Praxis Biologics, Inc. | Vaccines for nontypable haemophilus influenzae |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| EP0482068A1 (en) | 1989-07-14 | 1992-04-29 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| CA2039921A1 (en) | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| EP0467714A1 (en) | 1990-07-19 | 1992-01-22 | Merck & Co. Inc. | The class II protein of the outer membrane of neisseria meningitidis |
| EP0471177B1 (en) | 1990-08-13 | 1995-10-04 | American Cyanamid Company | Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines |
| ATE194657T1 (de) | 1990-09-25 | 2000-07-15 | Cantab Pharma Res | Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| AU681572B2 (en) | 1991-10-21 | 1997-09-04 | Med Immune, Inc. | Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| WO1993015115A1 (en) | 1992-01-24 | 1993-08-05 | Cornell Research Foundation, Inc. | E. coli dna polymerase iii holoenzyme and subunits |
| KR950700081A (ko) | 1992-02-11 | 1995-01-16 | W 로우 죤 | 이중 캐리어 면역원성 구성물 |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| WO1993021769A1 (en) | 1992-05-06 | 1993-11-11 | President And Fellows Of Harvard College | Diphtheria toxin receptor-binding region |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| ATE280235T1 (de) | 1993-03-05 | 2004-11-15 | Wyeth Corp | Plasmid zur herstellung von crm-protein und diphtherie-toxin |
| WO1994021807A2 (en) | 1993-03-19 | 1994-09-29 | Cantab Pharmaceuticals Research Limited | Defective mutant non-retroviral virus (e.g. hsv) as vaccine |
| ES2145072T3 (es) | 1993-05-13 | 2000-07-01 | American Cyanamid Co | Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos. |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| ES2310924T3 (es) | 1993-07-13 | 2009-01-16 | Centelion | Vectores adenovirales defectivos y utilizacion en terapia genica. |
| US5439808A (en) | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
| JPH09501055A (ja) | 1993-07-30 | 1997-02-04 | ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー | 初代リンパ球への効率的遺伝子転移 |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| ATE254475T1 (de) | 1993-09-22 | 2003-12-15 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
| US5550213A (en) | 1993-12-27 | 1996-08-27 | Rutgers, The State University Of New Jersey | Inhibitors of urokinase plasminogen activator |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2716459B1 (fr) | 1994-02-22 | 1996-05-10 | Univ Paris Curie | Système hôte-vecteur utilisable en thérapie génique. |
| WO1995026411A2 (en) | 1994-03-25 | 1995-10-05 | The Uab Research Foundation | Composition and methods for creating syngeneic recombinant virus-producing cells |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| WO1995028494A1 (en) | 1994-04-15 | 1995-10-26 | Targeted Genetics Corporation | Gene delivery fusion proteins |
| US5571515A (en) | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
| ES2128055T3 (es) | 1994-04-20 | 1999-05-01 | Us Army | Vacuna contra infecciones de bacterias gram-negativas. |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5565204A (en) | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| GB9422096D0 (en) | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| BE1008978A5 (fr) | 1994-12-27 | 1996-10-01 | Solvay | Adjuvants pour vaccins. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| EP0814833B1 (en) | 1995-03-22 | 2003-05-28 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
| AU6043396A (en) | 1995-06-05 | 1996-12-24 | University Of Alabama At Birmingham Research Foundation, The | Composition and methods for creating syngeneic recombinant v irus-producing cells |
| ATE339436T1 (de) | 1995-06-07 | 2006-10-15 | Sanofi Pasteur Inc | Expression von lipoproteinen |
| FR2741358B1 (fr) | 1995-11-17 | 1998-01-02 | Centre Nat Rech Scient | Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn |
| US5846547A (en) | 1996-01-22 | 1998-12-08 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
| US6355255B1 (en) | 1998-12-07 | 2002-03-12 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
| ATE208629T1 (de) | 1996-08-27 | 2001-11-15 | Chiron Corp | Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung |
| ATE252602T1 (de) | 1996-08-27 | 2003-11-15 | Chiron Corp | Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen |
| GB9622159D0 (en) | 1996-10-24 | 1996-12-18 | Solvay Sociutu Anonyme | Polyanionic polymers as adjuvants for mucosal immunization |
| WO1998017805A2 (en) | 1996-10-24 | 1998-04-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, c/o Centers for Disease Control and Prevention, Technology Transfer Office | Invasion associated genes from neisseria meningitidis serogroup b |
| GB9622660D0 (en) | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| KR20010020570A (ko) | 1997-06-30 | 2001-03-15 | 자끄 사비나 | 다세포 진핵 생물 세포중으로 개선된 핵산 전달방법 및이를 위한 콤비네이션 |
| CA2294793A1 (fr) | 1997-06-30 | 1999-01-14 | Rhone-Poulenc Rorer S.A. | Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede |
| CA2295029A1 (en) | 1997-06-30 | 1999-01-14 | Centre National De La Recherche Scientifique | Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo |
| AU748973B2 (en) | 1997-07-17 | 2002-06-13 | Baxter Healthcare Sa | Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide |
| JPH1144977A (ja) | 1997-07-25 | 1999-02-16 | Copyer Co Ltd | 画像形成装置 |
| ATE505478T1 (de) | 1997-08-27 | 2011-04-15 | Novartis Vaccines & Diagnostic | Molekular-mimetika von meningokokkalen b epitopen |
| ATE476508T1 (de) | 1997-11-06 | 2010-08-15 | Novartis Vaccines & Diagnostic | Neisseriale antigene |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| SG152917A1 (en) | 1998-01-14 | 2009-06-29 | Chiron Srl | Neisseria meningitidis antigens |
| WO1999040200A1 (en) | 1998-02-03 | 1999-08-12 | Center For Disease Control And Prevention | RECOMBINANT LIPIDATED PsaA PROTEIN, METHODS OF PREPARATION AND USE |
| GB9806456D0 (en) | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
| GB9808734D0 (en) | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| GB9808932D0 (en) | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
| EP2261341A3 (en) | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| ES2278446T3 (es) | 1998-05-29 | 2007-08-01 | Novartis Vaccines And Diagnostics, Inc. | Vacunas combinadas b/c contra la meningitis. |
| CA2340692A1 (en) | 1998-08-19 | 2000-03-02 | North American Vaccine, Inc. | Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide |
| ATE274353T1 (de) | 1998-09-30 | 2004-09-15 | Us Army | Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien |
| ES2293735T3 (es) | 1998-09-30 | 2008-03-16 | Wyeth Holdings Corporation | Holotoxina del colera mutante como coadyuvante. |
| CN1338005A (zh) | 1998-10-09 | 2002-02-27 | 希龙公司 | 奈瑟球菌基因组序列及其用途 |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6281337B1 (en) | 1998-11-12 | 2001-08-28 | Schering Corporation | Methods for conversion of protein isoforms |
| AU2289000A (en) | 1999-01-15 | 2000-08-01 | Smithkline Beecham Biologicals (Sa) | (neisseria meningitidis) polypeptide basb052 |
| WO2000043518A1 (en) | 1999-01-22 | 2000-07-27 | Smithkline Beecham Biologicals S.A. | Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| GB9902084D0 (en) | 1999-01-29 | 1999-03-24 | Smithkline Beecham Biolog | Novel compounds |
| PT1150712E (pt) | 1999-02-05 | 2008-12-22 | Merck & Co Inc | Formulações para a vacina do vírus do papiloma humano |
| AU2457100A (en) | 1999-02-26 | 2000-09-14 | Chiron S.P.A. | Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs |
| EP1162999B1 (en) | 1999-03-19 | 2006-11-29 | Glaxosmithkline Biologicals S.A. | Vaccine against Streptococcus pneumoniae |
| US6245568B1 (en) | 1999-03-26 | 2001-06-12 | Merck & Co., Inc. | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
| JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア |
| US7115730B1 (en) | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
| EP1228217B1 (en) | 1999-04-30 | 2012-11-21 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
| MXPA01011047A (es) | 1999-04-30 | 2003-10-14 | Chiron Corp | Secuencias genomicas de neisseria y metodos para su uso. |
| EP1860191A3 (en) | 1999-05-19 | 2008-02-13 | Novartis Vaccines and Diagnostics S.r.l. | Combination neisserial compositions |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
| US7384640B1 (en) | 1999-09-30 | 2008-06-10 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
| EP2275552B1 (en) | 1999-10-29 | 2015-09-09 | GlaxoSmithKline Biologicals SA | Neisserial antigenic peptides |
| DE60044005D1 (de) | 1999-11-29 | 2010-04-22 | Novartis Vaccines & Diagnostic | 85 kDa Antigen von Neisseria |
| GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
| WO2001041800A2 (en) | 1999-12-02 | 2001-06-14 | Chiron Corporation | Compositions and methods for stabilizing biological molecules upon lyophilization |
| EP2275129A3 (en) | 2000-01-17 | 2013-11-06 | Novartis Vaccines and Diagnostics S.r.l. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
| CN101139590B (zh) | 2000-02-28 | 2012-07-18 | 启龙股份公司 | 奈瑟球菌蛋白质的杂交表达 |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| RU2413520C2 (ru) | 2000-06-08 | 2011-03-10 | Интерселл Аг | Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды |
| AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| JP2005504718A (ja) | 2001-01-23 | 2005-02-17 | アヴェンティス パストゥール | 多価髄膜炎菌多糖−タンパク質複合ワクチン |
| GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| WO2002079246A2 (en) | 2001-03-30 | 2002-10-10 | Geneprot, Inc. | Human arginine-rich protein-related compositions |
| US6942802B2 (en) | 2001-04-13 | 2005-09-13 | Wyeth Holdings Corporation | Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography |
| CN1306956C (zh) | 2001-04-17 | 2007-03-28 | 希龙公司 | 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物 |
| AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| CN1541111A (zh) | 2001-06-07 | 2004-10-27 | ���Ͽع�����˾ | 作为佐剂的霍乱全毒素的突变形式 |
| US7285281B2 (en) | 2001-06-07 | 2007-10-23 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| WO2003009869A1 (en) | 2001-07-26 | 2003-02-06 | Chiron Srl. | Vaccines comprising aluminium adjuvants and histidine |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| JP2005508630A (ja) | 2001-09-14 | 2005-04-07 | インヴィトロジェン コーポレーション | Ｄｎａポリメラーゼとその変異体 |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| GB0129007D0 (en) | 2001-12-04 | 2002-01-23 | Chiron Spa | Adjuvanted antigenic meningococcal compositions |
| MXPA04009339A (es) | 2002-03-26 | 2005-01-25 | Chiron Srl | Sacaridos modificados que tienen estabilidad mejorada en agua. |
| WO2003094960A2 (en) | 2002-05-14 | 2003-11-20 | Chiron Srl | Mucosal combination vaccines for bacterial meningitis |
| MXPA04011249A (es) | 2002-05-14 | 2005-06-06 | Chiron Srl | Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos. |
| GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| GB0220198D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Modified saccharides,conjugates thereof and their manufacture |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| DE60335477D1 (de) | 2002-10-11 | 2011-02-03 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
| US20070059329A1 (en) | 2002-11-15 | 2007-03-15 | Nathalie Norais | Unexpected surface proteins in meningococcus |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| WO2004065603A2 (en) | 2003-01-15 | 2004-08-05 | Wyeth Holdings Corporation | Methods for increasing neisseria protein expression |
| PT2172213E (pt) * | 2003-01-30 | 2013-06-03 | Novartis Ag | Vacinas injetáveis contra múltiplos serogrupos meningocócicos |
| EP1603950A2 (en) | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| EP1618185A4 (en) | 2003-04-16 | 2009-05-27 | Wyeth Corp | NEW IMMUNOLOGICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCOULAR DISEASE |
| AU2004240558A1 (en) | 2003-05-07 | 2004-12-02 | Aventis Pasteur, Inc. | Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines |
| AU2004255526A1 (en) | 2003-05-07 | 2005-01-20 | Aventis Pasteur, Inc. | Method of enhanced immunogenicity to meningococcal vaccination |
| CA2528007C (en) | 2003-06-02 | 2012-03-27 | Chiron Corporation | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
| EP2364725A3 (en) | 2003-06-23 | 2012-05-09 | Sanofi Pasteur Inc. | Immunization method against neisseria meningitidis serogroups a and c |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| ATE506963T1 (de) | 2003-10-02 | 2011-05-15 | Novartis Vaccines & Diagnostic | Kombinationsimpfstoffe gegen meningitis |
| BRPI0417938A (pt) | 2003-12-30 | 2007-04-17 | Wyeth Corp | formulações de proteìnas hidrofóbicas em uma composição imunogênica que possui tolerabilidade aperfeiçoada |
| GB0406013D0 (en) | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
| GB0408978D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Meningococcal fermentation for preparing conjugate vaccines |
| GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| JP5718545B2 (ja) | 2004-04-30 | 2015-05-13 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 髄膜炎菌結合体ワクチン接種 |
| GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
| GB0411387D0 (en) | 2004-05-21 | 2004-06-23 | Chiron Srl | Analysis of saccharide length |
| GB0413868D0 (en) | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
| CN101014618B (zh) | 2004-07-23 | 2013-01-02 | 诺华疫苗和诊断有限公司 | 抗原的寡聚装配多肽 |
| GB0419408D0 (en) | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
| GB0419846D0 (en) | 2004-09-07 | 2004-10-13 | Chiron Srl | Vaccine adjuvants for saccharides |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| DK2682126T3 (en) | 2005-01-27 | 2017-02-27 | Children's Hospital & Res Center At Oakland | GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis |
| US20070014842A1 (en) | 2005-03-07 | 2007-01-18 | Denis Martin | Pharmaceutical liposomal compositions |
| CN101282984B (zh) | 2005-05-06 | 2013-05-08 | 诺华疫苗与诊断股份有限公司 | A型脑膜炎疫苗的免疫原 |
| PL2878307T3 (pl) | 2005-06-27 | 2020-01-31 | Glaxosmithkline Biologicals S.A. | Kompozycja immunogenna |
| CN101287488B (zh) | 2005-09-01 | 2013-01-30 | 诺华疫苗和诊断有限两合公司 | 含血清群c脑膜炎球菌的多价疫苗 |
| EP1922546B1 (en) | 2005-09-05 | 2010-10-20 | GlaxoSmithKline Biologicals S.A. | Serum bactericidal assay for n. meningitidis specific antisera |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| AU2006327023A1 (en) | 2005-12-23 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Conjugate vaccines |
| CA2646993C (en) | 2006-03-22 | 2016-01-26 | Novartis Ag | Regimens for immunisation with meningococcal conjugates |
| WO2007127668A2 (en) | 2006-04-26 | 2007-11-08 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| US20090246224A1 (en) | 2006-06-12 | 2009-10-01 | Nathalie Devos | Vaccine |
| GB0612854D0 (en) | 2006-06-28 | 2006-08-09 | Novartis Ag | Saccharide analysis |
| WO2008001224A2 (en) | 2006-06-29 | 2008-01-03 | Novartis Ag | Polypeptides from neisseria meningitidis |
| BRPI0715360B8 (pt) | 2006-07-27 | 2022-01-04 | Wyeth Corp | método para a produção de uma proteína recombinante; método para a produção de uma proteína 2086 meningocócica recombinante (p2086); e composição |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| US20100203137A1 (en) | 2007-06-04 | 2010-08-12 | Mario Contorni | Formulation of meningitis vaccines |
| US8540955B2 (en) | 2007-07-10 | 2013-09-24 | Wyeth Llc | Process for producing aluminum phosphate |
| GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| CA2695467A1 (en) | 2007-08-02 | 2009-03-26 | Children's Hospital & Research Center At Oakland | Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| NZ584683A (en) | 2007-10-19 | 2012-05-25 | Novartis Ag | Neisseria meningitidis serogroup B vaccine formulations |
| US9579372B2 (en) | 2008-02-21 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Meningococcal fHBP polypeptides |
| MX2010008799A (es) | 2008-03-05 | 2010-09-07 | Sanofi Pasteur | Proceso para estabilizar una composicion de vacuna que contiene adyuvante. |
| ES2557282T3 (es) | 2008-03-10 | 2016-01-25 | Children's Hospital & Research Center At Oakland | Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso |
| WO2009143168A2 (en) | 2008-05-19 | 2009-11-26 | Novartis Ag | Vaccine assays |
| US9387239B2 (en) | 2008-05-30 | 2016-07-12 | U.S. Army Medical Research And Materiel Command | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
| CA2734304A1 (en) | 2008-08-27 | 2010-03-11 | Children's Hospital & Research Center At Oakland | Complement factor h-based assays for serum bactericidal activity against neisseria meningitidis |
| US8470340B2 (en) | 2008-09-03 | 2013-06-25 | Children's Hospital & Research Center Oakland | Peptides presenting an epitope of a domain of factor H binding protein and methods of use |
| IT1394288B1 (it) | 2008-09-12 | 2012-06-06 | Novartis Vaccines & Diagnostic | Immunogeni di proteine che legano il fattore h. |
| EP3011953A1 (en) | 2008-10-29 | 2016-04-27 | Ablynx N.V. | Stabilised formulations of single domain antigen binding molecules |
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| BRPI0923006A2 (pt) | 2008-12-17 | 2016-03-08 | Novartis Ag | vacinas meningococicas incluindo receptor de hemoglobina |
| ES2797504T3 (es) | 2009-03-24 | 2020-12-02 | Glaxosmithkline Biologicals Sa | Proteína de enlace del factor H meningocócico utilizada como adyuvante |
| BRPI1009829A2 (pt) | 2009-03-24 | 2016-11-16 | Novartis Ag | combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos |
| NZ595361A (en) | 2009-04-30 | 2013-09-27 | Childrens Hosp & Res Ct Oak | Chimeric factor h binding proteins (fhbp) and methods of use |
| US9365885B2 (en) | 2009-06-16 | 2016-06-14 | Puiying Annie Mak | High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays |
| BR112012004275A2 (pt) | 2009-08-27 | 2016-11-16 | Novartis Ag | polipeptídios híbridos incluindo sequências meningocócicas de fhbp |
| WO2011039631A2 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
| GB0917647D0 (en) | 2009-10-08 | 2009-11-25 | Glaxosmithkline Biolog Sa | Expression system |
| EP2493499A1 (en) | 2009-10-27 | 2012-09-05 | Novartis AG | Modified meningococcal fhbp polypeptides |
| WO2011080595A2 (en) | 2009-12-30 | 2011-07-07 | Novartis Ag | Polysaccharide immunogens conjugated to e. coli carrier proteins |
| GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
| JP2013521326A (ja) | 2010-03-10 | 2013-06-10 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| WO2012020326A1 (en) | 2010-03-18 | 2012-02-16 | Novartis Ag | Adjuvanted vaccines for serogroup b meningococcus |
| BR122021020829B8 (pt) | 2010-03-30 | 2022-12-27 | Children´S Hospital & Res Center At Oakland | Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada |
| AU2011268507B2 (en) | 2010-06-25 | 2014-08-14 | Novartis Ag | Combinations of meningococcal factor H binding proteins |
| PT3246044T (pt) | 2010-08-23 | 2021-02-15 | Wyeth Llc | Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis |
| WO2012031271A1 (en) | 2010-09-04 | 2012-03-08 | Novartis Ag | Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines |
| US20120070457A1 (en) | 2010-09-10 | 2012-03-22 | J. Craig Venter Institute, Inc. | Polypeptides from neisseria meningitidis |
| GB201015132D0 (en) | 2010-09-10 | 2010-10-27 | Univ Bristol | Vaccine composition |
| AU2011300409B2 (en) | 2010-09-10 | 2015-03-26 | Wyeth Llc | Non-lipidated variants of Neisseria meningitidis ORF2086 antigens |
| AU2011300418B2 (en) | 2010-09-10 | 2016-05-12 | Glaxosmithkline Biologicals Sa | Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom |
| GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| US20140112950A1 (en) | 2011-03-02 | 2014-04-24 | Manmohan Singh | Combination vaccines with lower doses of antigen and/or adjuvant |
| WO2012134975A1 (en) | 2011-03-28 | 2012-10-04 | St. Jude Children's Research Hospital | Methods and compositions employing immunogenic fusion proteins |
| CA2863178C (en) | 2012-01-30 | 2021-04-06 | Serum Institute Of India Ltd. | Immunogenic composition |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| US8986710B2 (en) | 2012-03-09 | 2015-03-24 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| HK1206764A1 (en) | 2012-03-26 | 2016-01-15 | Axcella Health Inc. | Nutritive proteins and methods |
| EP2831102A4 (en) | 2012-03-26 | 2015-12-02 | Pronutria Inc | NUTRITIONAL FRAGMENTS, PROTEINS THEREFOR AND METHOD |
| WO2014136064A2 (en) * | 2013-03-08 | 2014-09-12 | Pfizer Inc. | Immunogenic fusion polypeptides |
| MX369534B (es) | 2013-09-08 | 2019-11-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos. |
| RU2723045C2 (ru) | 2015-02-19 | 2020-06-08 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их получения |
| IL255106B2 (en) | 2015-05-04 | 2023-04-01 | Pfizer | Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses |
| SG10202111092UA (en) | 2017-01-31 | 2021-11-29 | Pfizer | Neisseria meningitidis compositions and methods thereof |
-
2020
- 2020-09-24 CA CA3155669A patent/CA3155669A1/en active Pending
- 2020-09-24 AU AU2020355401A patent/AU2020355401B2/en active Active
- 2020-09-24 KR KR1020227013540A patent/KR102871663B1/ko active Active
- 2020-09-24 US US17/764,153 patent/US12383611B2/en active Active
- 2020-09-24 MX MX2022003682A patent/MX2022003682A/es unknown
- 2020-09-24 CN CN202080082380.1A patent/CN115605222A/zh active Pending
- 2020-09-24 EP EP20786082.6A patent/EP4034157A1/en active Pending
- 2020-09-24 WO PCT/IB2020/058928 patent/WO2021059181A1/en not_active Ceased
- 2020-09-24 BR BR112022004921A patent/BR112022004921A2/pt unknown
- 2020-09-25 JP JP2020160424A patent/JP2021066727A/ja active Pending
-
2022
- 2022-03-09 IL IL291239A patent/IL291239A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102871663B1 (ko) | 2025-10-16 |
| US20220401544A1 (en) | 2022-12-22 |
| JP2021066727A (ja) | 2021-04-30 |
| WO2021059181A1 (en) | 2021-04-01 |
| KR20220069992A (ko) | 2022-05-27 |
| AU2020355401A1 (en) | 2022-04-14 |
| US12383611B2 (en) | 2025-08-12 |
| CN115605222A (zh) | 2023-01-13 |
| AU2020355401B2 (en) | 2025-03-27 |
| IL291239A (en) | 2022-05-01 |
| EP4034157A1 (en) | 2022-08-03 |
| BR112022004921A2 (pt) | 2022-07-19 |
| MX2022003682A (es) | 2022-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7119245B2 (ja) | 髄膜炎菌組成物およびその方法 | |
| US20220118072A1 (en) | Neisseria meningitidis compositions and methods thereof | |
| AU2020355401B2 (en) | Neisseria meningitidis compositions and methods thereof | |
| RU2839906C9 (ru) | Композиции с Neisseria meningitidis и способы их применения | |
| RU2839906C1 (ru) | Композиции с Neisseria meningitidis и способы их применения | |
| HK40081069A (en) | Neisseria meningitidis compositions and methods thereof | |
| RU2780425C2 (ru) | Композиции neisseria meningitidis и способы | |
| NZ796387A (en) | Neisseria meningitidis compositions and methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220323 |
|
| EEER | Examination request |
Effective date: 20220323 |
|
| EEER | Examination request |
Effective date: 20220323 |
|
| EEER | Examination request |
Effective date: 20220323 |
|
| EEER | Examination request |
Effective date: 20220323 |
|
| EEER | Examination request |
Effective date: 20220323 |
|
| EEER | Examination request |
Effective date: 20220323 |
|
| EEER | Examination request |
Effective date: 20220323 |